Red Lesions
Erythroplakia
aka Erythroplasia of Queyrat (genital analogue)
A red velvety patch that cannot be attributed to any other definable lesion — the highest-risk oral premalignant disorder.
Red Flags
- ·Any red patch persisting > 2 weeks
- ·Induration or ulceration
- ·Cervical lymphadenopathy
- ·Floor of mouth or ventral tongue location
Clinical Tips
- ·Every persistent erythroplakia must be biopsied — do NOT observe.
- ·Assume malignancy until proven otherwise.
- ·Sample multiple sites if lesion is large.
Examination Checklist
- ·Full mucosal examination
- ·Palpation for induration
- ·Toluidine blue staining
- ·Photograph and measure
- ·Plan biopsy of most suspicious area
§ figuresFigures (0)
Verified clinical image not yet available
Verified open-access images only, reproduced for education under their stated licences · no AI-generated or illustrative artwork · Erythroplakia figures pending faculty review.
§ overviewOverview
WHO: 'A fiery red patch that cannot be characterised clinically or pathologically as any other definable disease.' Considered an oral potentially malignant disorder (OPMD).
§ icdICD Classification
ICD-10 K13.29
§ etiologyEtiology
- 01Heavy tobacco use
- 02Alcohol (synergistic)
- 03Areca nut
- 04Chronic Candida infection
- 05HPV (subset)
§ riskRisk Factors
- 01Male, 60–70 years
- 02Combined tobacco + alcohol
- 03Poor oral hygiene
§ geneticsGenetics & Molecular Biology
- 01Frequent TP53 mutations, LOH at 3p and 9p
- 02High DNA aneuploidy — strong progression marker
§ epidemiologyEpidemiology
Rare — prevalence 0.02–0.1%. Middle-aged to elderly men. Southeast Asia higher due to habits.
§ pathogenesisPathogenesis
Atrophic, non-keratinised epithelium overlying dysplastic or malignant cells → underlying vasculature shows through, producing bright red colour. Represents advanced field change on the OPMD spectrum.
§ clinicalClinical Features
- 01Bright red, velvety, well-demarcated plaque
- 02Flat or slightly depressed, soft on palpation
- 03Common sites: floor of mouth, ventral/lateral tongue, soft palate, retromolar area
- 04May be mixed with white areas (erythroleukoplakia)
- 05Usually asymptomatic; mild soreness or metallic taste
§ signsSigns & Symptoms
- 01Painless red patch
- 02Occasional burning or roughness
- 03Bleeds on gentle probing
§ differentialDifferential Diagnosis
- 01Erythematous candidiasis
- 02Lichen planus (atrophic/erosive)
- 03Mucositis
- 04Contact stomatitis
- 05Kaposi sarcoma
- 06Discoid lupus
- 07Early SCC
§ criteriaDiagnostic Criteria
- 01Diagnosis of exclusion; incisional biopsy mandatory in every case
§ histopathHistopathology
- 01Severe epithelial dysplasia, carcinoma in situ or invasive SCC in > 90% of cases at first biopsy
- 02Atrophic epithelium with reduced or absent keratinisation
- 03Sub-epithelial chronic inflammation and vascular ectasia (produces red colour)
- 04Loss of basement membrane integrity indicates invasion
§ investigationsInvestigations
- 01Toluidine blue (strongly positive)
- 02Autofluorescence loss
- 03Incisional/excisional biopsy — GOLD STANDARD
- 04HPV testing if history suggestive
§ ihcIHC / Special Stains
- 01p53 diffuse positivity
- 02Ki-67 full-thickness proliferation
- 03Cyclin D1 over-expression
§ whoWHO Classification
Classified under Oral Potentially Malignant Disorders (WHO 2022). Highest per-lesion transformation risk of all OPMDs.
§ classificationClassification
- 01Homogeneous erythroplakia
- 02Erythroleukoplakia (mixed red + white)
- 03Granular / speckled erythroplakia
§ planTreatment Planning
- 01Immediate biopsy of every red patch persisting > 2 weeks after removing irritants
- 02Complete surgical excision regardless of grade due to high malignant potential
- 03Neck assessment if invasive SCC found
§ treatmentTreatment
- 01Habit cessation
- 02Complete surgical excision with 5 mm margin
- 03CO2 laser excision acceptable for superficial lesions
- 04Definitive oncologic management if invasive SCC
§ medicalMedical Management
- 01Adjunctive antifungals if Candida co-infection
- 02Chemopreventive retinoids — limited evidence
§ surgicalSurgical Management
- 01Wide local excision with clear margins
- 02CO2 laser or cold-knife based on size and site
- 03Reconstruction with primary closure, secondary intention or graft
§ complicationsComplications
- 01Progression to invasive SCC
- 02Recurrence at margins
- 03Post-excisional scarring, tethering
§ recurrenceRecurrence Rate
Recurrence 20–30% even after complete excision; new lesions common due to field cancerisation.
§ followupFollow-up Protocol
- 01Monthly for first 3 months, then 3-monthly for 2 years, 6-monthly lifelong
- 02Re-biopsy any recurrence or new red area
§ prognosisPrognosis
Highest malignant potential of all OPMDs — up to 50% harbour or progress to invasive SCC within 5 years.
§ preventionPrevention
- 01Tobacco / alcohol / areca cessation
- 02Oral cancer screening in high-risk populations
§ examKey Examination Points
- 01Site, size, colour uniformity
- 02Induration and fixity
- 03Cervical lymph nodes
- 04Habit history
§ revisionQuick Revision Summary
- 01Red > white in risk
- 02> 90% dysplasia / CIS / SCC at first biopsy
- 03Excision mandatory regardless of grade
- 04Lifelong follow-up
§ vivaBDS Viva Questions
- 01Define erythroplakia.
- 02Why is it more dangerous than leukoplakia?
- 03What is the commonest histological finding?
- 04How is it managed?
- 05Name three differentials for a red mucosal patch.
- 06What is erythroleukoplakia?
- 07What is toluidine blue staining and its use here?
- 08What is field cancerisation?
§ bdsBDS Professional Examination
- 01Compare and contrast leukoplakia and erythroplakia (10 marks).
- 02Short note: Erythroplakia.
§ fcpsFCPS Residency Questions
- 01Discuss oral potentially malignant disorders with special reference to erythroplakia — molecular basis, clinical evaluation, and evidence-based management.
§ pearlsClinical Pearls
- 01Red > white — erythroplakia is more ominous than leukoplakia.
- 02Any red patch not diagnosable as candidiasis or lichen planus must be biopsied.
- 03Toluidine blue helps localise most dysplastic zones.
§ mnemonicsMnemonics
- 01RED = Really Every Dysplastic — biopsy every red patch
§ readingSuggested Reading
- 01Reichart PA, Philipsen HP. Oral erythroplakia — a review. Oral Oncol 2005.
- 02WHO Head & Neck Tumours 5e (2022).
§ differentialDifferential Comparison
| Entity | Feature | Distinguisher |
|---|---|---|
| Erythematous candidiasis | Red patch | Responds to antifungals; KOH positive |
| Atrophic lichen planus | Red areas with striae | Bilateral symmetrical, Wickham striae |
| Contact stomatitis | Red | History of allergen contact; resolves on removal |
| Early SCC | Red with induration | Induration, ulcer, invasive histology |
§ mcqsMCQs — Assessment (5)
Question 1
Erythroplakia most commonly shows on biopsy:
Question 2
Most common site of erythroplakia:
Question 3
Compared to leukoplakia, erythroplakia has:
Question 4
Management of persistent erythroplakia is:
Question 5
Erythroplakia is red because of:
§ evidenceReferences & Evidence
Current Classification
WHO Classification of Head and Neck Tumours
5th Edition — Volume 9
WHO Classification of Tumours Editorial Board · 2022
The authoritative international classification of head and neck, odontogenic and salivary gland tumours. Current terminology on this site follows this edition.
Evidence summary
Highest level of evidence linked to this page: WHO / Official Classification.
- L1 · Classification — 2
- L2 · Guideline — 1
- L3 · Systematic review — 1
- L6 · Textbook — 3
1 linked source was published from 2024 onwards. Where guidance is limited or contested, rely on the higher-level sources above rather than this summary. Educational use only — not a substitute for clinical judgement.
Content last reviewed
September 2026
Evidence last reviewed
September 2026
Next scheduled review
September 2027
Review status
EVIDENCE REVIEWED
Search latest PubMed evidence
Last literature search: 7 September 2026
Current Classification
WHO Classification of Tumours Editorial Board. IARC / World Health Organization · 2022
The authoritative international classification of head and neck, odontogenic and salivary gland tumours. Current terminology on this site follows this edition.
IARC / WHO. IARC · 2022
Continuously updated online edition of the WHO head and neck tumour classification.
Clinical Guidelines
Warnakulasuriya S, Kujan O, Aguirre-Urizar JM et al.. Oral diseases · 2021 · 27(8):1862-1880
WHO collaborating centre consensus on nomenclature and classification of oral potentially malignant disorders.
Systematic Reviews & Meta-Analyses
Walsh T, Liu JL, Brocklehurst P et al.. The Cochrane database of systematic reviews · 2013 · 2013(11):CD010173
Cochrane review of conventional oral examination and adjuncts for detecting oral cancer and potentially malignant disorders.
Histopathology References
Barnes L. CRC Press · 2008
Detailed histopathological reference for head and neck diagnostic criteria.
Textbook References
Neville BW, Damm DD, Allen CM et al.. Elsevier · 2024
Standard reference textbook of oral and maxillofacial pathology used throughout this atlas.
Rajendran R, Sivapathasundharam B. Elsevier · 2020
Undergraduate and postgraduate oral pathology textbook widely used in BDS and FCPS curricula.
Additional sources cited on this page
- Neville BW et al. Oral & Maxillofacial Pathology, 4e
- Warnakulasuriya S. Oral Oncol 2020
- WHO Classification of Head and Neck Tumours, 5e (2022)
Draft — pending faculty review. Educational use only; verify against current guidelines and primary sources before clinical application.